Synchron Raises $200M Series D to Boost BCI Commercialization and Develop Next-Gen Technology
Synchron announced a $200 million Series D financing round to advance the commercialization of its brain-computer interface (BCI) system. The New York-based company will use the funds to accelerate the rollout of its Stentrode BCI and to develop its next-generation interface.
This funding brings Synchron’s total capital raised to $345 million. It plans to speed up pivotal clinical trials and expand its team by hiring engineers, neuroscientists, and operators focused on next-gen BCIs.
Strategic Expansion and AI Integration
Synchron is growing its Cognitive AI division in New York to train models that decode brain signals in real time. Concurrently, a new engineering hub was launched in San Diego to build advanced brain interface technology.
Investment and Partnership Details
- Financing led by Double Point Ventures
- Existing investors include ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS
- New participants: Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT
About the Stentrode BCI
Synchron describes Stentrode as the only BCI implanted via an endovascular approach that detects motor intentions from blood vessels inside the brain.
The implant is placed on the surface of the motor cortex through the jugular vein, enabling less invasive brain signal capture compared to traditional methods.
Author’s Summary
Synchron’s $200 million raise will expedite Stentrode's commercialization while fueling next-gen BCI development through strategic expansion and AI integration.